Today, CADTH, on behalf of the Real-World Evidence Steering Committee, launched a public consultation to solicit feedback on a pan-Canadian guidance document that will inform the use of real-world evidence (RWE) that may be submitted for consideration in regulatory and reimbursement decision-making…
Today we are proud to mark World Evidence-Based Healthcare (EBHC) Day, a global initiative to highlight the critical role of evidence in improving health outcomes, enhancing clinical care, and informing policy .
The 2022 World EBHC Day campaign focuses on partnerships within the global evidence…
Six health technology assessment (HTA) bodies from 3 continents will join forces to collaborate on a range of topics to benefit people accessing health care around the world.
The signatories to the arrangement, who will continue to remain independent of one another, are:
National Institute for…
CADTH is pleased to announce the launch of its new Post-Market Drug Evaluation Program.
This important initiative fills a key gap in Canada’s drug safety and effectiveness landscape and is an exciting example of how CADTH is delivering on the “Innovate” pillar from its 2022-2025 Strategic Plan.…
We recently experienced problems with its website hosting platform that prevented users from downloading documents from cda-amc.ca – including draft reimbursement recommendations and stakeholder feedback forms.
The issue has been resolved and all documents on our website are now accessible to…
CADTH is pleased to announce the introduction of the Real-World Evidence (RWE) Guidance Working Group which reports to the Real-World Evidence Steering Committee. The objective of this Guidance Working Group is to develop clear and comprehensive guidance on the conduct, reporting, and appraising of…
Held in April or May every year since 2005, the CADTH Symposium has traditionally been a spring event.
Because of the COVID-19 pandemic, the 2020 CADTH Symposium was delayed until late fall and we continued with a fall date in 2021.
Now we are preparing for a return to the CADTH Symposium’s…
CADTH is pleased to announce the successful collaborators of its inaugural Post-Market Drug Evaluation (PMDE) Network. Collaborators will bring additional expertise to the PMDE Network and will respond to decision-makers’ queries by providing expertise and evidence in the post-market space.
The…
CADTH is pleased to announce the release of a new report entitled Building Toward a Potential Pan-Canadian Formulary: A Report From the Advisory Panel.
In July 2021, the Government of Canada approached CADTH to develop a recommended framework for creating and managing a potential pan-Canadian…
We are undertaking an innovative review for an antiviral treatment to address the recent monkeypox outbreaks.
Monkeypox has become a serious public health issue around the globe. According to WHO, the most recent case fatality ratio from monkeypox infection is about 3% to 6%. The causes of death…
CADTH is pleased to announce the 4 successful Core Network Partners of its inaugural Post-Market Drug Evaluation (PMDE) Network. Core Network Partners will be the foundation of the PMDE Network and will respond to decision-makers’ queries by providing expertise and evidence in the post-market space…
June 1, 2022 – the pan-Canadian health technology assessment body, will host a national roundtable on models of care for post–COVID-19 condition on June 1, 2022.
Post–COVID-19 condition, or long COVID, is characterized by persistent or lingering symptoms that continue for weeks, months, or years…